Arcturus Announces FDA Clears LEAP Technologies Platform
Arcturus confirms receipt of FDA clearance for its LEAP mRNA platform technology. This regulatory milestone underpins the development of its COVID-19 vaccine candidate, LURV126. Industry observers view this clearance as a vote of confidence in the platform's safety and scalability.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed